Zacks Rating on United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : 8 analysts are covering United Therapeutics Corporation (UTHR) and their average rating on the stock is 2.5, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

United Therapeutics Corporation (UTHR) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $229 and the lowest price target forecast is $95. The average forecast of all the analysts is $134.25 and the expected standard deviation is $40.2.


Shares of United Therapeutics Corporation rose by 3.53% in the last five trading days and 15.62% for the last 4 weeks. United Therapeutics Corporation is up 11.16% in the last 3-month period. Year-to-Date the stock performance stands at -17.22%. United Therapeutics Corporation (NASDAQ:UTHR): stock turned positive on Tuesday. Though the stock opened at $129.92, the bulls momentum made the stock top out at $130.55 level for the day. The stock recorded a low of $128.73 and closed the trading day at $129.64, in the green by 0.15%. The total traded volume for the day was 498,341. The stock had closed at $129.45 in the previous days trading.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.